Clinical trials: Retinal Vascular Disorder
Glaucoma, Diabetic Retinopathy
Uptake of Comprehensive Eye Examination Trial
1. To evaluate a educational intervention promoting acceptance of comprehensive eye examination in rural Guangdong. 2. To evaluate the impact of acceptance of comprehensive eye examination in rural Guangdong.
- Trial name
- NCT01743781
- Testing
- video
- Where
- China
- Volunteers
- 459 people
- Sponsor
- Sun Yat-sen University
Carotid Artery Injuries
Imagery of Retinal and Choroidal Variations Observed After a Revascularization Procedure on the Internal Carotid Artery
The purpose of this study is to describe the changes in morphology and Retinal vascularization after revascularization of the internal carotid artery.
- Trial name
- CAROCT-A (NCT03939351)
- Testing
- OCT-angiography and SD-OCT
- Where
- France
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Branch Retinal Vein Occlusion, Ranibizumab
Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
To investigate the efficacy of laser photocoagulation combined with ranibizumab intravitreal injection in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in long term.
- Conditions
- Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation
- Trial name
- NCT03054766
- Testing
- Ranibizumab combined macular laser, Ranibizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Hospital
Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in…
- Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- LUMINOUS (NCT01318941)
- Testing
- Ranibizumab
- Where
- 463 sites in Argentina, Australia and 41 more
- Volunteers
- 30,490 people
- Sponsor
- Novartis Pharmaceuticals
Central Serous Chorioretinopathy, Polypoidal Choroidal Vasculopathy
Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.
- Trial name
- NCT02815176
- Testing
- Blood sampling
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Diabetic Retinopathy
Treating Early Stage Diabetic Retinopathy
To determine if levodopa will slow the appearance of blood vessel changes in the eyes of patients with diabetes. Treatment will be started in patients with diabetes show delays in the electrical activity of the retina when…
- Trial name
- TESDR (NCT05132660)
- Testing
- Sinemet CR
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- VA Office of Research and Development
Central Retinal Vein Occlusion
Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)
Ranibizumab (Lucentis, Genentech) is an off-label drug used for the clinical treatment of central retinal vein occlusion, which is one of the most common retinal vascular disorders.
- Trial name
- NCT01303276
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Diabetic Retinopathy, Retinal Vein Occlusion
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in…
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
- Trial name
- OCTA-RVD (NCT04505618)
- Testing
- Swept-Source (SS) OCT Angiography, Spectral-Domain (SD) OCT Angiography, Fundus Imaging
- Where
- United States
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Diabetic Retinopathy
Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy.
Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus and the leading cause of preventable blindness in working-age individuals. Early screening for DR is a public health issue.
- Trial name
- ERGDIAB (NCT06782997)
- Testing
- Electroretinogram
- Where
- France
- Volunteers
- 270 people
- Sponsor
- CHU de Reims
Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy
PRP vs PRP+IVC for Severe nPDR
The randomized clinical trial aims to compare the therapeutic effects between panretinal photocoagulation(PRP) and PRP combined with intravitreal conbercept (IVC) injection in severe nPDR with/without diabetic macular edema…
- Conditions
- Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabete Mellitus
- Trial name
- NCT03863535
- Testing
- Conbercept, Panretinal coagulation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Compliance, Diabetic Retinopathy
a Trial of Using SMS Reminder Among Diabetic Retinopathy Patients in Rural China
The purpose of this study is to use a randomized controlled design to determine the impact of a SMS messaging intervention on the following outcomes among persons diagnosed with diabetic retinopathy in rural China.
- Conditions
- Compliance, Diabetic Retinopathy, SMS
- Trial name
- SMS (NCT01837121)
- Testing
- the SMS reminder message
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Sun Yat-sen University
Cataract, Glaucoma
Village-Integrated Eye Worker Trial II - Pilot
The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment.
- Conditions
- Cataract, Glaucoma, Age Related Macular Degeneration, Diabetic Retinopathy
- Trial name
- VIEW II Pilot (NCT03278587)
- Testing
- Community-based screening program, Cataract camp program, Community health worker program
- Where
- Nepal
- Volunteers
- 87,992 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Diabetes Type 1, Diabetic Retinopathy
Assessment of Retinal Microcirculation in Patients With Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is associated with an increased lifetime risk of developing diabetic retinopathy, a leading cause of visual impairment among working-age adults worldwide.
- Conditions
- Diabetes Type 1, Diabetic Retinopathy, Microvascular Circulation, Retinal Microvascular Disease
- Trial name
- NCT07705321
- Testing
- Optical Coherence Tomography Angiography (OCTA)
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Athens
Diabetic Retinopathy
Eye Screening in German Secondary Diabetes Care Centers
In patients with confirmed diagnosis of diabetes, an eye examination and a comprehensive survey are conducted after recruitment in secondary diabetes care centers.
- Trial name
- DiabCheckophta (NCT02311504)
- Testing
- OCT examination
- Where
- Germany
- Volunteers
- 831 people
- Sponsor
- University Hospital Tuebingen
Diabetic Retinopathy
Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.
- Trial name
- ARTDR (NCT06879834)
- Testing
- taking fundus photos using non-mydriatic fundus camera
- Where
- Ukraine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Wet Macular Degeneration
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of…
- Trial name
- MACBETH (NCT01896284)
- Testing
- 0.5mg aflibercept
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Barcelona Macula Foundation
Macular Edema, Macular Degeneration
Study Evaluating Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04428242
- Testing
- RHMS-RTM, SD-OCT
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Retinal Artery Occlusion, Central Retinal Artery Occlusion
The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain
Retinal stroke is a time-dependent neurovascular emergency associated with severe visual loss, increased risk of cerebrovascular events and substantial variability in clinical management.
- Conditions
- Retinal Artery Occlusion, Central Retinal Artery Occlusion, Retinal Ischemia, Cilioretinal Arteries
- Trial name
- GEIR (NCT07900230)
- Volunteers
- 500 people
- Sponsor
- Germans Trias i Pujol Hospital
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.